9 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic DrugSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorderActive, not recruitingPhase 32026-10-09NCT06641076
Long-Term Safety and Efficacy of Plozasiran in Adults With HypertriglyceridemiaDyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, hypertriglyceridemia, metabolic diseaseActive, not recruitingPhase 32026-10-01NCT06822790
A Study of Guselkumab in Participants With Active Psoriatic ArthritisSkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorderActive, not recruitingPhase 32026-09-25NCT04882098
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorderActive, not recruitingPhase 32026-09-04NCT05739383
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular DiseaseArterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorderActive, not recruitingPhase 32026-08-25NCT05030428
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.CNS demyelinating autoimmune disease, Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, autoimmune disorder of the nervous system, chronic progressive multiple sclerosis, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorderActive, not recruitingPhase 32026-08-17NCT06372145
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's SyndromePrimary Sjogrens DiseaseActive, not recruitingPhase 32026-04-16NCT06684847
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes TrialArterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorderActive, not recruitingPhase 32026-02-27NCT05581303
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapySkin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, bone disorder, musculoskeletal system disorder, psoriasis, psoriatic arthritis, skin disorder, spondylitis, vertebral column disorderActive, not recruitingPhase 32025-08-05NCT03675308